Recently, subfraction analysis of serum low density lipoprotein (LDL) is considered to be a better predictor of the risk of coronary heart disease (CHD) compared to the other lipid parameters. The aim of this study was to examine the effects of the HDL-associated Taq1B (rs708272) SNP of cholesterol ester transfer protein (CETP) gene on serum LDL subfractions in patients with CHD. Serum lipid levels were measured enzymatically and LDL subfraction analysis was carried out by the Lipoprint System (Quantimetrix, CA, USA). The CETP rs708272 SNP was studied in 66 healthy controls and 79 patients with CHD receiving statin therapy by the PCR-RFLP technique. The CHD patients had elevated antiatherogenic LDL-1 subfraction (p = 0.042), decreased atherogenic IDL-C subfraction (p = 0.023), and total IDL (p = 0.030) levels compared to the healthy controls. The CETP rs708272 Taq1B minor B2 allele was associated with increased levels of antiatherogenic LDL-1 (B2: 0.40 ± 0.20 vs. B1B1: 0.25 ± 0.08, p = 0.004) and large-LDL (LDL 1-2) subfractions in the CHD group (B2 allele: 0.68 ± 0.41 vs. B1B1: 0.42 ± 0.20; p < 0.05), while it was associated with reduced levels of the large-LDL subfraction in healthy subjects (B2 allele: 0.29 ± 0.14 vs. B1B1: 0.54 ± 0.24; p = 0.017). However, there was no statistically significant association between the CETP rs708272 SNP and small dense LDL subfraction (LDL 3-7) and lipoprotein levels (p > 0.05). Our findings have indicated that the CETP rs708272 SNP together with statin therapy may show a favorable effect on antiatherogenic LDL-1 and large-LDL subfractions in CHD patients with an atherogenic effect on large-LDL subfraction in healthy subjects. Based on these results, it can be concluded that the effects of the CETP variation on LDL subfraction could change in cardiometabolic events such as CHD and statin therapy.

The allelic and genotypic frequencies of the PPARG P12A (rs1801282) and PPARD +294T/C (rs52016520) variations were not different between the study groups (p>0.05), while PPARG C161T (rs3856806) CC genotype frequency was higher in the CHD patient group (p=0.029). The Serum LDL subfractions were observed to be only affected by the PPARG P12A variation. While PPARG P12A heterozygous ProAla genotype was associated with increased large-buoyant LDL subfractions (p=0.024), homozygous ProPro genotype was associated with high HDL cholesterol levels (p=0.033) in the control group. The PPARG Pro12Ala normal ProPro genotype was associated with increased triacylglycerol and LDL cholesterol levels (p=0.031 and p=0.010, respectively) and PPAR-B/D +294T/C minor C allele was associated with high LDL cholesterol levels (p=0.038) in the CHD group. There was no effect of the PPARG P12A variation on the lipoprotein subfractions in the CHD group. C Co on nc cl lu u--s si io on n: : We observed that the PPARG Pro12Ala normal ProPro genotype and PPAR-B/D +294T/C minor C allele show a detrimental effect on serum LDL-K levels, while they are not effective on the distribution of LDL subfractions in the CHD patients. However, it was observed that the PPARG ProAla genotype contribute the antiatherogenic large-buoyant LDL subfraction in normolipidemic subjects. As a result, it is possible that the effects of genetic variations of the PPARs on lipid and LDL subfractions may have been affected by cardiometabolic circumstances.K Ke ey yw wo or rd ds s:

Objective Fatty acid β-oxidation defects can lead to difficulties at covering energy requirement of heart. The carnitine-shuttle is responsible for the transfering of long-chain fatty acids from the internal mitochondrial membrane. The role of genetic variants of the enzymes in the carnitine shuttle in coronary artery disease (CAD) has not been studied. Therefore, we performed a case-control study investigating the possible relation between the CPTIA-rs3019613 and CROT-rs2214930 gene variations located carnitine shuttle and CAD risk. Materials and methods Study groups were comprised of 96 CAD patients and 85 controls. CPTIA-rs3019613 G > A and CROT-rs2214930 T > C polymorphisms were determined by real-time-PCR. Results The CROT-rs2214930-CC genotype was found to be associated with decreased HDL-cholesterol (HDL-C) in controls (p = 0.029). In patients with CPTIA-rs3019613-A allele, body mass index (BMI) (p = 0.016) and BMI threshold-value (p = 0.030) were found be higher compared to those with GG-genotype, while HDL-C threshold-value (HDL-C ≤ 0.90 mmol/L) was found to be lower (p = 0.015). Regression analysis confirmed CPTIA-rs3019613-A allele has a significant relationship with decreased HDL-C (p = 0.009) in patients. Conclusion Our study indicated that the polymorphisms of the CROT and CPTIA genes related to β-oxidation of long-chain fatty acids had an important effect on serum HDL-C levels and may be a potential risk for CAD.